CPPE’s Post

Fatigue, abnormal temperature, elevated heart rate. These are all elusive and vague symptoms that could imply a variety of conditions—including sepsis. Explore the science of Monocyte Distribution Width (MDW), a novel parameter for early sepsis detection and intervention in adult ED patients that’s part of a CBC-Diff on DxH 900 and 690T hematology analyzers. Learn More: https://bit.ly/3sIBkmV #WorldSepsisDay #WSD #SepsisAwareness #Sepsis #StopSepsis #SaveLives #ED #MDW

Fatigue, abnormal temperature, elevated heart rate. These are all elusive and vague symptoms that could imply a variety of conditions—including sepsis. Explore the science of Monocyte Distribution Width (MDW), a novel parameter for early sepsis detection and intervention in adult ED patients that’s part of a CBC-Diff on DxH 900 and 690T hematology analyzers. Learn More: https://bit.ly/3sIBkmV #WorldSepsisDay #WSD #SepsisAwareness #Sepsis #StopSepsis #SaveLives #ED #MDW

Fatigue, abnormal temperature, elevated heart rate. These are all elusive and vague symptoms that could imply a variety of conditions—including sepsis. Explore the science of Monocyte Distribution Width (MDW), a novel parameter for early sepsis detection and intervention in adult ED patients that’s part of a CBC-Diff on DxH 900 and 690T hematology analyzers. Learn More: https://bit.ly/3sIBkmV #WorldSepsisDay #WSD #SepsisAwareness #Sepsis #StopSepsis #SaveLives #ED #MDW

Interested in more updates in myelofibrosis? Check out the Journal of Clinical Pathways' Myelofibrosis Resource Center!   Click here for the latest news 👉 https://lnkd.in/e9n_kyMD #JournalOfClinicalPathways #CancerCare #MyelofibrosisResourceCenter #Myelofibrosis

Fatigue, abnormal temperature, elevated heart rate. These are all elusive and vague symptoms that could imply a variety of conditions—including sepsis. Explore the science of Monocyte Distribution Width (MDW), a novel parameter for early sepsis detection and intervention in adult ED patients that’s part of a CBC-Diff on DxH 900 and 690T hematology analyzers. Learn More: https://bit.ly/3sIBkmV #WorldSepsisDay #WSD #SepsisAwareness #Sepsis #StopSepsis #SaveLives #ED #MDW

Employee health benefits that actually benefit PEOPLE. Take a look at our insightful webinar discussing HealthEZ's Medical Infusion Program (MICO) and learn how we put the patient at the center of everything that we do while continuing to control and predict cost for employee benefits. #HealthEZ #MICO #MedicalInfusions #CostContainment

Here is a quick update for those of you that missed our webinar discussing HealthEZ’s Medical Infusion Carve-Out Program. The presentation is available below and if you have any questions or would like to discuss opportunities feel free to reach out to me.

Facing Parkinson’s Disease often means coping with daily challenges like stiffness, freezing, and fatigue. Our therapeutic devices help alleviate these symptoms, providing hope and support throughout your journey. Discover how Gladiator Therapeutics is committed to helping change lives. https://ow.ly/JuSm50SxsKG #GladiatorTherapeutics #Parkinsons #ParkinsonsDisease #ParkinsonsSymptoms #ParkinsonsResearch #PatentedTechnology

Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol (a type of fat) and proteins in the blood. If you are 18 or older and have experienced a major cardiovascular event (like a heart attack or stroke), you may be eligible to participate in clinical research focused on lowering Lp(a). A new therapy is being developed to potentially lower high levels of Lp(a). Learn more at https://e.lilly/4efOk6x

Bayer announced that FINEARTS-HF met its primary endpoint, achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits. The randomized, double-blind, placebo-controlled, parallel-group, multi-center phase III cardiovascular outcomes study evaluated the efficacy and safety of KERENDIA® (finerenone) for investigational new use in patients with HF with a LVEF≥40% (left ventricular ejection fraction). Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with CKD associated with T2D. Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/gnuY5zf9 # Finerenone # KERENDIA # HF # LVEF # MRA # CKD # T2D # Chemenu # building blocks